Thermo Fisher Scientific Specialty Diagnostics — Selling, general and administrative expenses decreased by 1.7% to $175.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 1.7%, from $178.00M to $175.00M. This is a positive signal — lower values indicate better performance for this metric.
High spending relative to revenue may indicate investment in growth, whereas excessive spending can signal operational bloat.
Operating expenses incurred by the Specialty Diagnostics segment for non-production activities, including sales force co...
Benchmarkable against peers to determine the efficiency of the segment's commercial organization.
tmo_segment_specialty_diagnostics_selling_general_and_administrative_expenses| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q3 '25 | |
|---|---|---|---|---|---|---|
| Value | $179.00M | $179.00M | $179.00M | $179.00M | $178.00M | $175.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -0.6% | -1.7% |
| YoY Change | — | — | — | — | -0.6% | -1.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.